Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer With Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2017.00329
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Positive Response to Neoadjuvant Cyclophosphamide and Doxorubicin in Topoisomerase II Nonamplified/Her2/Neu Negative/Polysomy 17 Absent Breast Cancer Patients

Cancer Management and Research
Oncology
2010English

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Adjuvant Rituximab, a Potential Treatment for the Young Patient With Graves’ Hyperthyroidism (RiGD): Study Protocol for a Single-Arm, Single-Stage, Phase II Trial

Yearbook of Paediatric Endocrinology
2019English

A microRNA Signature Associated With Pathological Complete Response to Novel Neoadjuvant Therapy Regimen in Triple-Negative Breast Cancer

Tumor Biology
MedicineCancer Research
2017English

P2-033Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Dose Dense in Stage III Breast Cancer

Annals of Oncology
MedicineOncologyHematology
2018English

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Oncologist
Cancer ResearchMedicineOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy